DRMA Stock Analysis: Buy, Sell, or Hold?
DRMA - Dermata Therapeutics, Inc. Common Stock
$2.02
-0.23 (-10.22%)
▼
5d:
-34.42%
30d:
-12.93%
90d:
-41.11%
WAIT
LOW Confidence
Last Updated: February 2, 2026
Earnings: Mar 16, 2026
Get Alerted When DRMA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
11 traders called DRMA this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: DRMA is down 34.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: DRMA is down 34.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: DRMA is currently trading at $2.02, which is considered fair relative to its 30-day fair value range of $1.99 to $2.53.
Technical Outlook: Technically, DRMA is in a strong downtrend. The price is currently testing key support at $1.98. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 10.2% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $10.00 (+395.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, DRMA is in a strong downtrend. The price is currently testing key support at $1.98. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 10.2% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $10.00 (+395.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$1.99 -
$2.53
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.5%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-10.2%)
- BULLISH: Trading 395.0% below Wall St target ($10.00)
- WARNING: Recommendation downgraded due to -34.4% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$1.99 -
$2.53
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$1.98
Resistance Level
$4.66
Current Trend
Strong Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
-0.67
Wall Street Target
$10.00
(+395.0%)
Last updated: February 03, 2026 4:56 AM ET
Data refreshes hourly during market hours. Next update: 5:56 AM
Data refreshes hourly during market hours. Next update: 5:56 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DRMA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$404 | 62 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$213 | 61 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$56 | 59 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 54 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 56 HOLD |
